News

The new TCR candidates are directed against the HPV type 16 E6 oncoprotein incorporating gene editing and lentiviral technologies to efficiently modify certain genes to improve T cell

The new intravenous antiplatelet agent adds to the company’s commercial offerings in the cardiac cath lab. The company intends to introduce kengreal, which is the first and only

L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based upon its new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental

The company said that this marks the first FDA approved starting material from its Chinese subsidiary ANP, and signifies that this facility has been qualified by the FDA.

The move has been facilitated by the start of a collaboration between Benitec and ReNeuron, a UK-based stem cell therapeutics firm. The new program will use Benitec’s ddRNAi

Encenicline is a new alpha 7 agonist currently in Phase III development to treat cognitive impairment in schizophrenia and Alzheimer’s disease (AD). Recently, the company completed patient enrollment

The deal will add two quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, to Pfizer Ireland Pharmaceuticals’ portfolio. Nimenrix is a single dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine

AMG 334 is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, which is believed to transmit signals that can cause incapacitating pain. A

The funds, provided to the Ontario Institute for Regenerative Medicine (OIRM) 150 stem cell and regenerative medicine scientists, clinicians and engineers, will be used to examine new chronic